AP NEWS

Promethera Biosciences Appoints Mutsuki Takano to Group Chief Financial Officer

October 5, 2018

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Oct 5, 2018--Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced that Mutsuki Takano, currently Branch General Manager of Promethera Biosciences Japan Branch and Member of the Management Team of Promethera Biosciences SA will succeed Frank Hazevoets as Group Chief Financial Officer (Group CFO), in addition to his current responsibilities.

“We look forward to working with Mutsuki in his expanded role as Group Chief Financial Officer and General Manager of our branch office in Japan. The management change reflects the greater importance of the Asian markets for Promethera,” commented John Tchelingerian, PhD, President and CEO at Promethera. “On behalf of both the Board and the Executive Management, I would like to express my heartfelt thanks to Frank Hazevoets for his commitment to helping build Promethera over the past four years. We wish him all the best for the future.”

“I am honored to serve Promethera Biosciences as part of the global leadership team in addition to leading the expansion of our business development and corporate development activities in Asia,” commented Mutsuki Takano, Group Chief Financial Officer and Branch General Manager of Promethera Biosciences Japan Branch Ltd.

About Promethera Biosciences

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to enable patients to overcome acute and chronic liver diseases. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline we develop antibody technologies, such as the anti-TNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert, Belgium, Durham, NC, USA, Tokyo, Japan and Basel, Switzerland.

Promethera®, HepaStem®, H2stem®, Cytonet®, Heparesc® are all registered trademarks of the PROMETHERA group.

LinkedIn: https://www.linkedin.com/company/promethera-biosciences

Twitter: https://twitter.com/Promethera

View source version on businesswire.com:https://www.businesswire.com/news/home/20181005005058/en/

CONTACT: Promethera Biosciences SA

Alexandra Schiettekatte

Alexandra.schiettekatte@promethera.com

Web:www.promethera.com

or

For media:

MacDougall Communications

Mario Brkulj or Shai Biran, Ph.D.

+49 89 2420 9345

or +1 781-235-3060

promethera@macbiocom.com

KEYWORD: BELGIUM EUROPE

INDUSTRY KEYWORD: STEM CELLS HEALTH BIOTECHNOLOGY RESEARCH OTHER SCIENCE SCIENCE GENERAL HEALTH

SOURCE: Promethera Biosciences

Copyright Business Wire 2018.

PUB: 10/05/2018 03:00 AM/DISC: 10/05/2018 03:00 AM

http://www.businesswire.com/news/home/20181005005058/en

AP RADIO
Update hourly